Novo Nordisk's acquisition journey is driven by price pressure and a hunger for innovation
Acquisitions have been par for the course at Novo Nordisk in recent years. The pharmaceutical company has entered into a long list of collaboration deals and partnerships, which CEO Lars Fruergaard Jørgensen tells MedWatch is intended to lead to more innovation and treatments – and is a trend he expects to continue.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
Home is where the heart is, as the old saying goes. But in the Danish suburb of Bagsværd, some 12 kilometers northwest of Copenhagen, Denmark’s biggest pharmaceutical company Novo Nordisk is showing signs that it holds a different view.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
.jpg)
Novo Nordisk closes Dicerna acquisition deal
For subscribers
